BRPI0822238B8 - composições compreendendo ácidos graxos insaturados e compostos liberadores de óxido nítrico - Google Patents

composições compreendendo ácidos graxos insaturados e compostos liberadores de óxido nítrico

Info

Publication number
BRPI0822238B8
BRPI0822238B8 BRPI0822238A BRPI0822238A BRPI0822238B8 BR PI0822238 B8 BRPI0822238 B8 BR PI0822238B8 BR PI0822238 A BRPI0822238 A BR PI0822238A BR PI0822238 A BRPI0822238 A BR PI0822238A BR PI0822238 B8 BRPI0822238 B8 BR PI0822238B8
Authority
BR
Brazil
Prior art keywords
compositions
fatty acids
preventing
nitric oxide
unsaturated fatty
Prior art date
Application number
BRPI0822238A
Other languages
English (en)
Portuguese (pt)
Inventor
Pan Yuanlong
Original Assignee
Nestec Sa
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40853324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0822238(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa, Nestle Sa filed Critical Nestec Sa
Publication of BRPI0822238A2 publication Critical patent/BRPI0822238A2/pt
Publication of BRPI0822238B1 publication Critical patent/BRPI0822238B1/pt
Publication of BRPI0822238B8 publication Critical patent/BRPI0822238B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
BRPI0822238A 2008-01-04 2008-12-19 composições compreendendo ácidos graxos insaturados e compostos liberadores de óxido nítrico BRPI0822238B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1009708P 2008-01-04 2008-01-04
US61/010,097 2008-01-04
US13738208P 2008-07-30 2008-07-30
US61/137,382 2008-07-30
PCT/US2008/013870 WO2009088433A1 (en) 2008-01-04 2008-12-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions

Publications (3)

Publication Number Publication Date
BRPI0822238A2 BRPI0822238A2 (pt) 2015-06-30
BRPI0822238B1 BRPI0822238B1 (pt) 2020-03-10
BRPI0822238B8 true BRPI0822238B8 (pt) 2021-05-25

Family

ID=40853324

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822238A BRPI0822238B8 (pt) 2008-01-04 2008-12-19 composições compreendendo ácidos graxos insaturados e compostos liberadores de óxido nítrico

Country Status (11)

Country Link
US (4) US20100233304A1 (https=)
EP (2) EP2224930B1 (https=)
JP (1) JP5979816B2 (https=)
CN (2) CN105267969A (https=)
AU (1) AU2008347177B2 (https=)
BR (1) BRPI0822238B8 (https=)
CA (2) CA2994586C (https=)
ES (2) ES2773928T5 (https=)
MX (1) MX337760B (https=)
RU (1) RU2500402C2 (https=)
WO (1) WO2009088433A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
ES2731298T3 (es) 2005-05-27 2019-11-14 Univ North Carolina Chapel Hill Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas
ES2664777T5 (es) * 2007-10-04 2021-10-25 Nestle Sa Composiciones y procedimientos para mejorar la función cognitiva
CN102170792A (zh) * 2008-07-18 2011-08-31 希尔氏宠物营养品公司 提高老龄动物生活质量的方法
AU2013200758B2 (en) * 2008-07-18 2014-06-12 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
CA2771389C (en) 2009-08-21 2019-04-09 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US20120171303A1 (en) * 2009-09-11 2012-07-05 Nestec S.A. Compositions and methods for ehnancing cognitive and related functions in animals
ES2634034T5 (es) * 2009-12-29 2020-09-18 Nestle Sa Composiciones nutricionales con copos de fruta que contienen ácido docosahexenoico
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
CN102552457A (zh) * 2010-12-24 2012-07-11 漆又毛 一种氨基酸和提取物组合物的药物用途
RU2597793C2 (ru) 2011-01-25 2016-09-20 Нестек С.А. Способы и композиции для лечения, ослабления или предотвращения ухудшения зрительной системы животных
JP2014514248A (ja) * 2011-02-18 2014-06-19 ネステク ソシエテ アノニム 動物の神経系への損傷を治療、軽減、又は予防するための方法及び組成物
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
JP2014515011A (ja) * 2011-03-18 2014-06-26 ネステク ソシエテ アノニム 加齢に伴う疾病を改善するのに有用な組成物及び方法
AT511776B1 (de) * 2011-07-26 2014-03-15 Gonadosan Gmbh Verwendung von citrullin und ein kombinationspräparat zur verbesserung der männlichen fertilität
US20130059028A1 (en) * 2011-09-01 2013-03-07 Julie Marie Foy Compositions and Methods for Providing a Life-Stage-Appropriate Animal Diet
CN102600124B (zh) * 2012-02-06 2014-03-26 单宝华 Omega-3增强组合物及其应用
US10369186B2 (en) * 2012-10-30 2019-08-06 Kyowa Hakko Bio Co., Ltd. Method of treating decline in brain function comprising coadministration of citrulline and glutathione
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
CN103609752B (zh) * 2013-12-02 2016-05-25 内蒙古伊利实业集团股份有限公司 一种改善脑部认知功能的组合物及其制备方法与应用
WO2015094263A1 (en) * 2013-12-19 2015-06-25 Hill's Pet Nutrition, Inc. Method for determining spoilage of high protein foods
WO2015160234A1 (en) * 2014-04-17 2015-10-22 N.V. Nutricia Composition for brain improvement
RU2017114438A (ru) * 2014-10-10 2018-10-26 Нестек Са Композиции и способы повышения подвижности или активности или лечения дряхлости
PT3215143T (pt) * 2014-10-22 2021-08-31 Again Life Italia Srl Combinação compreendendo espirulina e palmitoíletanolamida
EP3223623A1 (en) * 2014-12-29 2017-10-04 Hill's Pet Nutrition, Inc. Food composition and method of use
ES2860427T3 (es) * 2015-06-22 2021-10-05 Nestle Sa Composiciones y métodos para mejorar la neurogénesis en animales
CN105602998A (zh) * 2016-01-18 2016-05-25 青岛哈拿生物科技有限公司 一种水溶性天然一氧化氮的制作方法及应用
JP2019518744A (ja) * 2016-05-27 2019-07-04 ネステク ソシエテ アノニム 運動障害を治療又は予防するための栄養組成物
US11813233B2 (en) * 2016-09-29 2023-11-14 Societe Des Produits Nestle S.A. Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US10849852B2 (en) * 2017-03-18 2020-12-01 High Plains Nutrition, Llc Pet food including cannabidiolic acid
CN110381935A (zh) * 2017-04-11 2019-10-25 雀巢产品有限公司 用于识别和减轻个体的认知衰老的ω-3脂肪酸和维生素D水平
IL296055A (en) 2017-08-14 2022-10-01 Axcella Health Inc Amino acid compositions for the treatment of liver disease
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
WO2022191184A1 (ja) * 2021-03-08 2022-09-15 国立大学法人九州大学 グレリン受容体感受性増強剤、グレリン受容体感受性増強用組成物及びグレリン受容体の活性化方法
EP4449875A1 (en) 2023-04-18 2024-10-23 Mars, Incorporated Composition for use for improving or preserving mental health in canine

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2018A (en) * 1841-03-26 Joseph francis
US6294520B1 (en) 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
IT1264987B1 (it) * 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
BR9607336A (pt) † 1995-02-23 1997-11-25 Novartis Nutrition Ag Composições de aminoácidos e utilidades das mesmas em nutrição clinica
EP0832652B8 (en) * 1996-09-19 2006-05-03 Sk Chemicals Co., Ltd. Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US7135498B1 (en) * 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
IL147112A0 (en) * 1999-06-14 2002-08-14 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
JP4669095B2 (ja) † 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
WO2007115282A2 (en) * 2006-04-03 2007-10-11 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US20050002992A1 (en) † 2003-06-17 2005-01-06 Mccleary Edward Larry Foods, beverages, condiments, spices and salad dressings with specialized supplements
US20040043013A1 (en) * 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
JP4304982B2 (ja) * 2001-03-23 2009-07-29 味の素株式会社 抗ストレス性疾患剤
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
DE10131516B4 (de) † 2001-07-02 2004-05-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Steuereinheit zur Flussregulierung
WO2003032804A2 (en) † 2001-10-12 2003-04-24 Cornell Research Foundation, Inc. Reversing or preventing premature vascular senescence
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US7514107B2 (en) * 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
US20040001817A1 (en) 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
JP2006520335A (ja) † 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
ES2479944T3 (es) † 2003-07-03 2014-07-25 Hill's Pet Nutrition, Inc. Composiciones y métodos para disminuir el deterioro ligado a la edad en las actividades mentales de los animales de compañía
US6951658B1 (en) † 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
US20060280776A1 (en) 2003-09-02 2006-12-14 Masafumi Koide Diet food
WO2005061684A1 (ja) † 2003-12-22 2005-07-07 Wakunaga Pharmaceutical Co., Ltd. 油脂組成物
US20060002985A1 (en) † 2004-07-02 2006-01-05 Zicker Steven C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
DK1830883T3 (da) † 2004-12-29 2013-11-25 Hills Pet Nutrition Inc Fremgangsmåde til at hæmme en nedgang i indlæring og/eller hukommelse hos dyr
CA2592827C (en) † 2004-12-30 2013-08-13 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a growing animal
US8148325B2 (en) 2004-12-30 2012-04-03 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
CN1810257A (zh) * 2005-05-26 2006-08-02 钟健琳 活脑素口服液
CN101981586A (zh) 2005-06-30 2011-02-23 皇家飞利浦电子股份有限公司 用于选择信息的方法和系统
BRPI0613358A8 (pt) † 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
EP1919304B1 (en) * 2005-08-26 2011-05-25 Nestec S.A. Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis after an ischemic episode in the brain
JP2009510117A (ja) † 2005-09-30 2009-03-12 ネステク ソシエテ アノニム 認知機能向上のための方法及び組成物
US20090286879A1 (en) † 2005-12-02 2009-11-19 Kiyoshi Hashizume Preventive or Therapeutic Drug for Alzheimer-Type Dementia
DK1800675T3 (da) 2005-12-23 2011-09-05 Nutricia Nv Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens
ES2664777T5 (es) 2007-10-04 2021-10-25 Nestle Sa Composiciones y procedimientos para mejorar la función cognitiva
EP2939314B1 (en) 2012-12-31 2018-08-29 Mitel Networks Corporation Interface adapter

Also Published As

Publication number Publication date
AU2008347177B2 (en) 2014-04-17
ES2773928T3 (es) 2020-07-15
RU2500402C2 (ru) 2013-12-10
EP2224930A1 (en) 2010-09-08
US20170157182A1 (en) 2017-06-08
WO2009088433A1 (en) 2009-07-16
CA2709660A1 (en) 2009-07-16
EP2224930B1 (en) 2016-06-15
US11951137B2 (en) 2024-04-09
JP5979816B2 (ja) 2016-08-31
MX337760B (es) 2016-03-17
RU2010132637A (ru) 2012-02-10
ES2773928T5 (es) 2023-06-28
CA2994586C (en) 2020-07-21
BRPI0822238A2 (pt) 2015-06-30
US20190030088A1 (en) 2019-01-31
EP3058942A1 (en) 2016-08-24
EP2224930A4 (en) 2011-06-22
US20210205373A1 (en) 2021-07-08
US10111911B2 (en) 2018-10-30
US20100233304A1 (en) 2010-09-16
ES2586757T3 (es) 2016-10-18
BRPI0822238B1 (pt) 2020-03-10
CN105267969A (zh) 2016-01-27
CA2709660C (en) 2018-06-05
CN101909632A (zh) 2010-12-08
EP3058942B2 (en) 2023-03-22
CA2994586A1 (en) 2009-07-16
EP3058942B1 (en) 2019-12-04
US10973859B2 (en) 2021-04-13
AU2008347177A1 (en) 2009-07-16
JP2011508773A (ja) 2011-03-17

Similar Documents

Publication Publication Date Title
BRPI0822238B8 (pt) composições compreendendo ácidos graxos insaturados e compostos liberadores de óxido nítrico
MX2010003568A (es) Composiciones y metodos para mejorar la funcion cognitiva.
BR112021021301A2 (pt) Derivados de ácido itacônico e usos dos mesmos no tratamento de uma doença inflamatória ou de uma doença associada a uma resposta imune indesejável
WO2011031304A3 (en) Compositions and methods for enhancing cognitive and related functions in animals
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
ATE549394T1 (de) Für tiere geeignete probiotische zusammensetzung
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
EA201591754A1 (ru) Человеческие антитела к na1.7
NZ778131A (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EA201790377A1 (ru) Антитела к глюкагону и их применения
BR112014029967A2 (pt) leitos para animais com baixo teor de poeira e métodos para fabricação dos mesmos
EA201270566A1 (ru) Противомикробные соединения и способы их получения и применения
MX380725B (es) Composiciones de urolitidina para mejorar la función mitocondrial y tratar condiciones patológicas relacionadas a los músculos
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
BR112015026207A2 (pt) uso de uma preparação na fabricação de uma composição nutricional, composição nutricional, uso de uma composição nutricional, uso de uma composição, composição, e método para tratamento ou fornecimento de gerenciamento nutricional de pacientes com hiperfenilalaninemia e/ou pacientes com fenilcetonúria
MY149171A (en) Treatment and prevention of influenza
WO2014054981A3 (ru) Способ стимуляции роста и повышения резистентности сельскохозяйственных животных
EA201500913A1 (ru) Противомикробные соединения и способы их получения и применения
BR112016010159A2 (pt) usos de um conjunto de ácidos nucleicos e de um chip de microarranjo, chip de microarranjo, métodos para detecção de patógenos e/ou microrganismos benéficos em uma amostra orgânica e de tratamento de uma relva doente, e, kit
BR112015029619A2 (pt) derivados de 1,3-diaminociclopentano carboxamida
BR112016002028A2 (pt) processo para o tratamento das fibras queratínicas, composição cosmética e kit
JP2015535241A5 (https=)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: SOCIETE DES PRODUITS NESTLE S.A. (CH)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF